Literature DB >> 34037470

MiR-494-3p alleviates acute lung injury through regulating NLRP3 activation by targeting CMPK2.

Hong Wang1, Shuqin Wang2, Shanshan Huang2.   

Abstract

Acute lung injury (ALI) is a severe respiratory disorder with a high rate of mortality, and is characterized by excessive cell apoptosis and inflammation. MicroRNAs (miRNAs) play pivotal roles in ALI. This study examined the biological function of miR-494-3p in cell apoptosis and inflammatory response in ALI. For this, mice were injected with lipopolysaccharide (LPS) to generate an in-vivo model of ALI (ALI mice), and WI-38 cells were stimulated with lipopolysaccharide (LPS) to generate an in-vitro model of ALI. We found that miR-494-3p was significantly downregulated in the ALI mice and in the in-vitro model. Overexpression of miR-494-3p inhibited inflammation and cell apoptosis in the LPS-induced WI-38 cells, and improved the symptoms of lung injury in the ALI mice. We then identified cytidine/uridine monophosphate kinase 2 (CMPK2) as a novel target of miR-494-3p in the WI-38 cells. Furthermore, miR-494-3p suppressed cell apoptosis and the inflammatory response in LPS-treated WI-38 cells through targeting CMPK2. The NLRP3 inflammasome is reportedly responsible for the activation of inflammatory processes. In our study, CMPK2 was confirmed to activate the NLRP3 inflammasome in LPS-treated WI-38 cells. In conclusion, miR-494-3p attenuates ALI through inhibiting cell apoptosis and the inflammatory response by targeting CMPK2, which suggests the value of miR-494-3p as a target for the treatment for ALI.

Entities:  

Keywords:  CMPK2; NLRP3 inflammasome; acute lung injury; atteinte pulmonaire aiguë; inflammasome NLRP3; miR-494-3p

Year:  2021        PMID: 34037470     DOI: 10.1139/bcb-2020-0243

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  1 in total

1.  Electroacupuncture Inhibits NLRP3 Activation by Regulating CMPK2 After Spinal Cord Injury.

Authors:  Yi Chen; Lei Wu; Mengting Shi; Danyi Zeng; Rong Hu; Xingying Wu; Shijun Han; Kelin He; Haipeng Xu; XiaoMei Shao; Ruijie Ma
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.